Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Future Cardiology

• Publication date

  2015-06-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fca.15.38PMID 26090568
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.

  2015cited by this paper
• Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.

  2015cited by this paper
• Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.

  2014cited by this paper
• Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report

  2014cited by this paper
• Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications

  2013cited by this paper
• ‘2012 focused update of the ESC Guidelines for the management of atrial fibrillation’ [Eur Heart J (2012); 33(21):2719–2747]

  2013cited by this paper
• Hemorragias en pacientes anticoagulados: utilidad real de los antídotos y modo de actuación con los nuevos anticoagulantes orales

  2013cited by this paper
• Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates

  2013cited by this paper
• Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

  2013cited by this paper
• In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban

  2013cited by this paper
• A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

  2013cited by this paper
• Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Revised A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

  2010cited by this paper
• A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

  2010cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

  2008cited by this paper

• Medical and Surgical Management of Colorectal Cancer Patients Presenting with Haemostatic Disorders

  2019cites this paper
• Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non–vitamin K Anticoagulant Reversal

  2018cites this paper
• The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review

  2018cites this paper
• Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial.

  2016influential citation